FDA Advisory Panel Will Evaluate Abbott’s MitraClip Next Month
This article was originally published in The Gray Sheet
Executive Summary
Abbott to present data showing MitraClip is safer option for inoperable patients.
You may also be interested in...
FDA Advisors Vote That Benefits Of Abbott’s MitraClip Outweigh Risks
The agency’s Circulatory System Devices Panel narrowly voted in favor of Abbott’s MitraClip transcatheter mitral valve repair system to reduce mitral regurgitation. But the discussions about the clinical evidence on the technology were complex and the panel’s support for Abbott’s PMA was not unanimous.
FDA Advisors Vote That Benefits Of Abbott’s MitraClip Outweigh Risks
The agency’s Circulatory System Devices Panel narrowly voted in favor of Abbott’s MitraClip transcatheter mitral valve repair system to reduce mitral regurgitation. But the discussions about the clinical evidence on the technology were complex and the panel’s support for Abbott’s PMA was not unanimous.
Four Firms Vie For Medicare 2014 New-Tech Add-On Payments
CMS held its annual new-technology Town Hall Feb. 5, hearing from applicants for a drug-eluting peripheral artery stent, a neurostimulator system for epilepsy seizures, a transcatheter mitral valve repair system and a retinal prosthesis system.